RG2077 (CTLA4-IgG4m)

I removed “RG2077 (aka CTLA4-IgG4m) (Immune Tolerance Network and Repligen)” from the phase 2 list because the Immune Tolerance Network is not pursuing development of this drug. According to a press release, “ACCLAIM is a follow-up trial to an earlier ITN-led open label phase I trial that was not conducted with abatacept but examined CTLA4IgG4m, a similar protein that blocks/reduces activation of T cells and helps regulate the immune system. Samia J. Khoury, M.D., a neurologist and co-director of the Partners MS Center at Brigham and Women’s Hospital in Boston, directed this trial. Dr. Khoury also is the principal investigator of the ACCLAIM trial. Results from the phase I trial showed that “CTLA4IgG4m was well tolerated and prevented or reduced Tcell activation in MS. The data suggested that it may be a promising approach to modifying the inflammatory process associated with MS.”


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: